Spahn Wealth & Retirement LLC purchased a new stake in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 13,756 shares of the biotechnology company's stock, valued at approximately $8,175,000. Axon Enterprise makes up 5.4% of Spahn Wealth & Retirement LLC's holdings, making the stock its 4th biggest holding.
A number of other hedge funds have also recently added to or reduced their stakes in the company. Asset Dedication LLC increased its position in Axon Enterprise by 11.3% in the 4th quarter. Asset Dedication LLC now owns 178 shares of the biotechnology company's stock worth $106,000 after buying an additional 18 shares during the period. Bleakley Financial Group LLC raised its position in shares of Axon Enterprise by 1.3% during the fourth quarter. Bleakley Financial Group LLC now owns 1,527 shares of the biotechnology company's stock valued at $908,000 after buying an additional 20 shares during the last quarter. Venturi Wealth Management LLC lifted its stake in shares of Axon Enterprise by 2.7% in the fourth quarter. Venturi Wealth Management LLC now owns 802 shares of the biotechnology company's stock valued at $477,000 after buying an additional 21 shares during the period. Insigneo Advisory Services LLC grew its position in Axon Enterprise by 1.4% during the third quarter. Insigneo Advisory Services LLC now owns 1,568 shares of the biotechnology company's stock worth $627,000 after buying an additional 22 shares in the last quarter. Finally, Menard Financial Group LLC increased its stake in Axon Enterprise by 0.8% during the third quarter. Menard Financial Group LLC now owns 3,014 shares of the biotechnology company's stock valued at $1,204,000 after acquiring an additional 24 shares during the period. Institutional investors and hedge funds own 79.08% of the company's stock.
Wall Street Analyst Weigh In
AXON has been the subject of a number of research reports. TD Cowen assumed coverage on Axon Enterprise in a research report on Wednesday, January 8th. They issued a "buy" rating and a $700.00 price objective for the company. JMP Securities reaffirmed an "outperform" rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. Northcoast Research lowered shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a report on Wednesday, February 19th. Needham & Company LLC reaffirmed a "buy" rating and set a $600.00 price objective on shares of Axon Enterprise in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group upped their target price on shares of Axon Enterprise from $500.00 to $700.00 and gave the company a "buy" rating in a research note on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $604.67.
Check Out Our Latest Report on Axon Enterprise
Insider Transactions at Axon Enterprise
In other news, Director Jeri Williams sold 307 shares of the business's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $552.72, for a total transaction of $169,685.04. Following the completion of the sale, the director now owns 1,627 shares in the company, valued at $899,275.44. The trade was a 15.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 6.10% of the stock is owned by company insiders.
Axon Enterprise Price Performance
Axon Enterprise stock traded up $19.67 on Tuesday, reaching $522.22. The company's stock had a trading volume of 296,003 shares, compared to its average volume of 807,957. The business's fifty day moving average price is $580.21 and its 200 day moving average price is $556.67. The company has a market cap of $40.01 billion, a price-to-earnings ratio of 134.94, a PEG ratio of 5.17 and a beta of 1.13. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. Axon Enterprise, Inc. has a twelve month low of $273.52 and a twelve month high of $715.99.
About Axon Enterprise
(
Free Report)
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Featured Stories
Before you consider Axon Enterprise, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axon Enterprise wasn't on the list.
While Axon Enterprise currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
